Abstract Library

#4090 Octreotide infusion pump in patients with functional neuroendocrine tumors and refractory hormonal syndromes

Introduction: In patients with metastatic functional neuroendocrine tumors (NETs), symptoms are, sometimes, not adequately controlled with long-acting somatostatin analogues (LASSAs), so patients need to use boost subcutaneous (sc) octreotide injections (inj) daily. However, this approach is not always effective and convenient for the patients.

Conference:

Presenting Author: Thuringer J

Authors: Thuringer J, Parker G, Sarma A, Hayes A, Mandair D,

Keywords: carcinoid syndrome, VIPoma, Octreotide, pump, refractory, subcutaneous,

#4085 Disease-specific mortality in a single-center cohort of 427 patients with carcinoid syndrome

Introduction: The carcinoid syndrome (CS), the most prevalent hormonal syndrome in patients with a neuroendocrine tumor (NET), is associated with impaired survival. Due to the biological behaviour of NET and overall improvement in survival rates, patients with CS may not succumb to their disease. However, the contribution of NET-specific death in these patients is currently unknown.

Conference:

Presenting Author: Maas C

Authors: Maas C, Mulders M, Feelders R, de Herder W, Hofland J,

Keywords: carcinoid syndrome, neuroendocrine tumor, prognosis, survival analysis,

#4020 Ovarian neuroendocrine tumor metastases can induce estrogen production in postmenopausal patients

Introduction: Neuroendocrine tumors (NET) are malignant neoplasms that can be associated with specific hormonal syndromes.

Conference:

Presenting Author: Mulders M

Authors: Mulders M, Hofland J, de Herder W, van Velthuysen M, Roes E,

Keywords: ovary, neuroendocrine, tumor, estradiol, postmenopausal, bleeding,

#3721 No multiple endocrine neoplasia type 1 (MEN1) Patient died from pancreaticoduodenal neuroendocrine tumor – Results from long-term follow-up of the Uppsala model of early diagnosis and treatment

Introduction: Progression of pancreaticoduodenal neuroendocrine tumor (P-NET) disease is the main death cause among MEN1 carriers. Although surgery is the only cure, indications vary substantially between centers. The Uppsala model of MEN1 management encompasses early diagnosis and treatment, aiming at lifelong malignancy prevention with preserved endocrine function. During three decades, all MEN1 patients harbouring P-NETs of at least 1 cm have been considered for surgery.

Conference:

Presenting Author:

Authors: Bajic D, Kjaer J, Welin S, Norlén O, Öberg K,

Keywords: multiple endocrine neoplasia type 1, pancreatic neuroendocrine tumor, indication for surgery, malignancy prevention,

#3071 Hormonal Ectopic Secretion Syndromes Associated to Neuroendocine Neoplasia

Introduction: Neuroendocrine neoplasias (NEN) are able to produce and secrete bioactive peptides and cause distinct syndromes related to their biological effects. The outcome will depend on the oncological disease as well as the hormonal syndrome

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Belli S

Authors: Belli S, Tkatch J, O'Connor J, Martinez M, Paissan A,

Keywords: ectopic secretion, hormonal syndrome, neuroendocrine neoplasia,